Tenon Medical, Inc.: Tenon Medical Announces FDA Clearance of Catamaran SI Joint Fusion System for New Indication to Augment Spinal Fusion
Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or ...
Morningstar4d
Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion
With this approval, the Catamaran is now indicated to treat the SI joint as either a stand-alone treatment or to augment a spinal fusion. "The FDA has cleared the Catamaran SI Joint Fusion System ...
Carl Zeiss Meditec AG: ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach
ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has ...
Medindia6d
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
Sky Medical Technology enters a distributor agreement with SMS Medical in the US to offer the geko� device for the elimination of edema (swelling) and blood clot (DVT) prevention following orthopaedic ...
The Manila Times1d
Preliminary Results from IDE Study on Ringer™ Perfusion Balloon Catheter (PBC) Reported from Podium at CTO Plus Conference
Ringer™ PBC is a rapid-exchange percutaneous transluminal coronary angioplasty (PTCA) catheter with a unique helical balloon.
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.
The Crimson White1d
Alabama student’s death by suicide reflects problems with veterans mental health treatment
Hunter Whitley always wanted to be a Marine.  “That was his lifelong dream,” said Shannon McDaniel, Whitley’s mother. “We ...
Targeting FDA user fees would leave agency gutted, experts say
Critics worry that the user fee program creates a conflict of interest between the FDA and pharmaceutical companies.
News Medical on MSN1d
Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...
News Medical2d
Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment ... 2024 European Society for Medical Oncology Congress and ...